Dai Maruyama

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study

Shigeru Kusumoto, Yasuhito Tanaka, Ritsuro Suzuki et al. · Clinical Infectious Diseases · 2015 · 149 citations · Full text

Medicine, Hematology, Oncology +15

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 140 citations

Medicine, Hematology, Oncology +15

Primary Bone Lymphoma: A New and Detailed Characterization of 28 Patients in a Single-Institution Study

Dai Maruyama, Takashi Watanabe, Yasuo Beppu et al. · Japanese Journal of Clinical Oncology · 2007 · 86 citations · Full text

Medicine, Oncology, Pathology +13